Am­gen diss­es drug pric­ing bill, while amp­ing $4B rare drug com­pa­ny deal and up­com­ing Hu­mi­ra biosim launch

Add Am­gen CEO Bob Brad­way to the cho­rus of phar­ma CEOs lament­ing the pend­ing drug pric­ing leg­is­la­tion in the US Sen­ate.

“For some time, we’ve been ad­vo­cat­ing for re­forms that re­spect in­no­va­tion and pro­vide im­proved ac­cess to it. The pro­posed bill does nei­ther. The bill will im­pose price con­trols, and price con­trols will stymie in­no­va­tion … When it comes to in­no­va­tion and af­ford­abil­i­ty, this bill is a lose-lose for pa­tients,” Brad­way said in his open­ing re­marks dur­ing Am­gen’s Q2 earn­ings call on Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER